Native Labs secures pre-seed investment led by Zinc VC to deploy artificial intelligence in therapy manufacturing.
Zinc VC has led a pre-seed funding round in Native Labs to accelerate platform deployment and feature development.
Native Labs develops artificial intelligence platforms to address manufacturing bottlenecks in the production of cell and gene therapies. The company combines advanced technology with industry expertise to support biopharma development.
Native Labs has secured pre-seed investment in a funding round led by Zinc VC. The capital will support the deployment of the company's artificial intelligence platform into manufacturing sites and process development laboratories, alongside further product development.
The business focuses on addressing production bottlenecks within the cell and gene therapy sector. Its founding team brings industrial and academic experience to the biopharma manufacturing space.
From the founder
"This is an important inflection point in Native Labs’ journey working with cell and gene therapy manufacturers. This funding will enable Native Labs to continue working in partnership with the industry, doubling down on solving the most acute pain points that our customers face. Due to the flexibility that our AI architecture enables, we are able to quickly iterate and expand the capability of our platform, meaning we can develop new features at pace. We would like to take this opportunity to thank Zinc VC and everyone else who has been a part of our journey. I am looking forward to sharing more progress in the very near future"
Louis Brookstein
CEO at Native Labs
Investor perspective
"We are excited to be partnering with the Native Labs team as they build the critical infrastructure required to accelerate the development and delivery of cell therapies. Their platform is addressing one of the most challenging bottlenecks in the field, enabling more seamless, data-driven communication between developers and manufacturers. In a market that is growing rapidly, and with the potential to transform patient outcomes, Native Labs is not only solving a deeply complex technical challenge but unlocking a massive opportunity for impact across the entire cell and gene therapy ecosystem."
Emilie Syed
Zinc
Use of funds
- 01Continue product development
Investors
Categories
About the company
Native Labs
Native Labs builds artificial intelligence technology to improve cell and gene therapy manufacturing.